# EDGAR Filing Document

**Accession Number:** 0001746473
**File Stem:** 0001193125-26-140923
**Filing Date:** 2026-4
**Character Count:** 2635
**Document Hash:** ea44c22b0eb72574724524d2cb7a347b
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-140923.hdr.sgml**: 20260506

**ACCESSION NUMBER**: 0001193125-26-140923

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20260402

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** PLIANT THERAPEUTICS, INC.
- **CENTRAL INDEX KEY:** 0001746473
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 474272481
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **STREET 1:** 331 OYSTER POINT BOULEVARD
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080
- **BUSINESS PHONE:** 650-481-6770

**MAIL ADDRESS:**
- **STREET 1:** 331 OYSTER POINT BOULEVARD
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080

**<u>VIA EDGAR</u>**

April 2, 2026

United States Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

Attention: Mr. Tyler Howes

---

| | |
|:---|:---|
| **Re:** | **Pliant Therapeutics, Inc.**  |

---

**Acceleration Request for Registration Statement on Form S-3**

**File No. 333-294737** 

---

| | |
|:---|:---|
| **Acceleration Request** | **Acceleration Request** |
| **Requested Date:** | **April 6, 2026** |
| **Requested Time:** | **4:15 p.m., Eastern Time** |

---

Dear Mr. Howes:

Pursuant to Rule 461 under the Securities Act of 1933, as amended (the "**Act**"), Pliant Therapeutics, Inc. (the "**Company**") hereby requests that the effective date of the above-referenced registration statement (the "**Registration Statement**") be accelerated to April 6, 2026, at 4:15 p.m., Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act.

Once the Registration Statement is effective, please orally confirm the event with our counsel, Goodwin Procter LLP, by calling Marianne Sarrazin at (415) 733-6134.

If you have any questions regarding this request, please contact Marianne Sarrazin of Goodwin Procter LLP at (415) 733-6134.

---

| |
|:---|
| Sincerely, |
| PLIANT THERAPEUTICS, INC. |
| */s/ Keith Cummings* |
| Keith Cummings, MD, MBA |
| Chief Financial Officer |

---

cc:

Deepa Rich, Esq., *Goodwin Procter LLP*

Marianne Sarrazin, Esq., *Goodwin Procter LLP*

Sam Zucker, Esq., *Goodwin Procter LLP*